Drug-induced Valvulopathy: An Update
Open Access
- 17 August 2010
- journal article
- review article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 38 (6), 837-848
- https://doi.org/10.1177/0192623310378027
Abstract
Drug-induced valvulopathy is a serious liability for certain compound classes in development and for some marketed drugs intended for human use. Reports of valvulopathy led to the withdrawal of fenfluramines (anorexigens) and pergolide (antiparkinson drug) from the United States market in 1997 and 2007, respectively. The mechanism responsible for the pathogenesis of valvulopathy by these drugs is likely a result of an “off-target” effect via activation of 5-hydroxytryptamine (5-HT) 2B receptor (5-HT2BR) expressed on heart valve leaflets. Microscopically, the affected valve leaflets showed plaques of proliferative myofibroblasts in an abundant extracellular matrix, composed primarily of glycosaminoglycans. However, the valvular effects caused by fenfluramines and pergolide were not initially predicted from routine preclinical toxicity studies, and to date there are no specific validated animal models or preclinical/toxicologic screens to accurately predict drug-induced valvulopathy. This review covers the structure and function of heart valves and highlights major advances toward understanding the 5-HT2BR-mediated pathogenesis of the lesion and subsequently, development of appropriate animal models using novel techniques/experiments, use of functional screens against 5-HT2BR, and more consistent sampling and pathologic evaluation of valves in preclinical studies that will aid in avoidance of future drug-induced valvulopathy in humans.Keywords
This publication has 90 references indexed in Scilit:
- Fenfluramine Disrupts the Mitral Valve Interstitial Cell Response to SerotoninThe American Journal of Pathology, 2009
- Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2BReceptor Agonists: Implications for Drug Safety AssessmentPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2009
- Appetite Suppressants, Cardiac Valve Disease and Combination PharmacotherapyClinical Journal of Sport Medicine, 2009
- Identification and Characterization of Aortic Valve Mesenchymal Progenitor Cells with Robust Osteogenic Calcification PotentialThe American Journal of Pathology, 2009
- Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individualsBMC Medicine, 2008
- Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse diseaseCardiovascular Pathology, 2008
- Abundance and location of proteoglycans and hyaluronan within normal and myxomatous mitral valvesCardiovascular Pathology, 2008
- Periostin regulates atrioventricular valve maturationDevelopmental Biology, 2008
- The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve PathobiologyThe American Journal of Pathology, 2007
- The Myofibroblast: One Function, Multiple OriginsThe American Journal of Pathology, 2007